Janux Therapeutics Inc [JANX] stock prices are down -2.48% to $24.77 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The JANX shares have gain 9.50% over the last week, with a monthly amount drifted -17.46%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Janux Therapeutics Inc [NASDAQ: JANX] stock has seen the most recent analyst activity on December 03, 2024, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $70 from $63. Previously, BTIG Research reaffirmed its Buy rating on December 03, 2024, and elevated its price target to $100. On November 22, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $79 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $69 on October 24, 2024. Stifel initiated its recommendation with a Buy and recommended $70 as its price target on September 06, 2024. Scotiabank started tracking with a Sector Perform rating for this stock on May 30, 2024, and assigned it a price target of $47. In a note dated March 21, 2024, BTIG Research initiated an Buy rating and provided a target price of $62 on this stock.
The stock price of Janux Therapeutics Inc [JANX] has been fluctuating between $22.48 and $71.71 over the past year. Currently, Wall Street analysts expect the stock to reach $72.33 within the next 12 months. Janux Therapeutics Inc [NASDAQ: JANX] shares were valued at $24.77 at the most recent close of the market. An investor can expect a potential return of 192.01% based on the average JANX price forecast.
Analyzing the JANX fundamentals
The Janux Therapeutics Inc [NASDAQ:JANX] reported sales of 9.34M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -12.17%, Pretax Profit Margin comes in at -8.33%, and Net Profit Margin reading is -8.33%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.09 and Total Capital is -0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Janux Therapeutics Inc [NASDAQ:JANX]’s Current Ratio is 58.47. On the other hand, the Quick Ratio is 58.47, and the Cash Ratio is 4.21. Considering the valuation of this stock, the price to sales ratio is 156.93, the price to book ratio is 1.45.
Transactions by insiders
Recent insider trading involved Meyer Andrew Hollman, Chief Business Officer, that happened on May 01 ’25 when 3333.0 shares were sold. Officer, ANDREW MEYER completed a deal on May 01 ’25 to buy 3333.0 shares. Meanwhile, Chief Business Officer Meyer Andrew Hollman sold 3334.0 shares on Apr 21 ’25.
